Chandler Robinson net worth and biography

Chandler Robinson Biography and Net Worth

Dr. Robinson co-founded Monopar and has served as its CEO since its inception in 2014. Dr. Robinson leverages his interests in medicine, science, and finance to help bring new therapeutics to patients. The compound Dr. Robinson researched at Northwestern University as an undergraduate and published on in Science completed a Phase III clinical trial for Wilson Disease, meeting its primary endpoint; he is now helping advance it to an NDA filing at Monopar. Among his previous experiences, Dr. Robinson worked in 2008 at Onyx Pharmaceuticals in their Nexavar marketing division; from 2008 to 2009 as a co-manager of a healthcare clinic in San Jose, CA; from 2006 to 2007 at Bear Stearns investment bank; and from 2004 to present as Founder and President of an undergraduate research focused non-profit. He was previously co-founder and CEO of Tactic Pharma, co-founder and board member of Wilson Therapeutics (acquired by Alexion, now AstraZeneca), and is currently on the board of Northwestern University's Chemistry of Life Processes Institute. Dr. Robinson graduated summa cum laude from Northwestern University, and earned a master's degree in International Health Policy and Health Economics from the London School of Economics on a Fulbright Scholarship, an MBA from Cambridge University on a Gates Scholarship, and an MD from Stanford University.

What is Chandler Robinson's net worth?: The estimated net worth of Chandler Robinson is at least $3.91 million as of July 14th, 2025. Robinson owns 73,472 shares of Monopar Therapeutics stock worth more than $3,912,384 as of May 1st. This net worth evaluation does not reflect any other investments that Robinson may own. Learn More about Chandler Robinson's net worth.
How do I contact Chandler Robinson?: The corporate mailing address for Robinson and other Monopar Therapeutics executives is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. Monopar Therapeutics can also be reached via phone at 847-388-0349 and via email at [email protected]. Learn More on Chandler Robinson's contact information.
Has Chandler Robinson been buying or selling shares of Monopar Therapeutics?: Chandler Robinson has not been actively trading shares of Monopar Therapeutics during the last ninety days. Most recently, Chandler Robinson sold 16,800 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a transaction totalling $672,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,472 shares of the company's stock, valued at $2,938,880. Learn More on Chandler Robinson's trading history.
Who are Monopar Therapeutics' active insiders?: Monopar Therapeutics' insider roster includes Andrew Cittadine (COO), Chandler Robinson (CEO), Christopher Starr (Director), Kim Tsuchimoto (Director), and Quan Vu (CFO). Learn More on Monopar Therapeutics' active insiders.
Are insiders buying or selling shares of Monopar Therapeutics?: In the last twelve months, Monopar Therapeutics insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $104,925.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 592,733 shares worth more than $36,700,226.69. The most recent insider tranaction occured on December, 26th when CFO Quan Anh Vu bought 1,500 shares worth more than $104,925.00. Insiders at Monopar Therapeutics own 20.5% of the company. Learn More about insider trades at Monopar Therapeutics.
Information on this page was last updated on 12/26/2025.

Chandler Robinson Insider Trading History at Monopar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/14/2025	Sell	16,800	$40.00	$672,000.00	73,472

Chandler Robinson Buying and Selling Activity at Monopar Therapeutics

Monopar Therapeutics Company Overview

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Today's Range

Now: $53.25

$50.60

$53.45

50 Day Range

MA: $55.75

$50.12

$61.53

2 Week Range

Now: $53.25

$28.40

$105.00

Volume

79,108 shs

Average Volume

226,668 shs

Market Capitalization

$356.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64